← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Iit Research Institute
Chicago, IL
$70,476,067
Total funding
43
Grants
Funding over time
peak $12.1M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$70,446,667 · 40
NSF$29,400 · 3
By mechanism
N01$65,228,066 · 34
R01$4,223,691 · 3
K01$808,958 · 1
R03$184,942 · 1
—$29,400 · 3
N02$1,010 · 1
Investigators at Iit Research Institute
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
STUDIES TO EVALUATE THE TOXIC AND CARCINOGENIC POTENTIAL OF CELL PHONE RADIATION$9,475,212
N01 · FY2011 · ES
Preclinical Toxicology and Pharmacology of Drugs for Cancer$7,000,000
N01 · FY2010 · CA
In Vitro and Animal Models for Emerging Infectious Diseases and Biodefense$3,255,000
N01 · FY2008 · AI
IGF::OT::IGF Support for the Aerosol Development of Bexarotene HHSN2612015000240 TO: HHSN26100004 PoP: 9/18/2017 to 9/17/2019$2,597,086
N01 · FY2017 · CA
STUDIES TO EVALUATE THE TOXIC AND CARCINOGENIC POTENTIAL OF CELL PHONE RADIATION$2,307,740
N01 · FY2010 · ES
Task D8: Nonclinical Services for Interventional Agents against SARS-CoV-2$1,883,524
N01 · FY2022 · AI
Preclinical Toxicology and Pharmacology of Drugs for Cancer$1,741,870
N01 · FY2008 · CA
IGF::OT::IGF PRECLINICAL PREVENT TOXICOLOGY AND PHARMACOLOGY$1,531,900
N01 · FY2016 · CA
STUDIES TO EVALUATE THE TOXIC AND CARCINOGENIC POTENTIAL OF CELL PHONE RADIATION$1,498,502
N01 · FY2015 · ES
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS$1,456,819
N01 · FY2023 · CA
NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO)$1,425,732
N01 · FY2023 · DA
Preclinical Pharmacology and Toxicology Studies$1,357,588
N01 · FY2008 · CA
TOXICOLOGY STUDIES IN MICE AND DOGS ADMINISTERED MTX-531$1,339,008
N01 · FY2024 · CA
Preclinical Toxicology and Pharmacology of Drugs for Cancer$1,322,758
N01 · FY2010 · CA
In Vitro And In Vivo Screening of chemopreventive agents$1,047,642
N01 · FY2010 · CA
PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREV$1,020,618
N01 · FY2024 · CA
In Vitro And In Vivo Screening of chemopreventive agents$1,017,128
N01 · FY2009 · CA
In Vitro And In Vivo Screening of chemopreventive agents$981,566
N01 · FY2008 · CA
Preclinical Efficacy Evaluation of the Lipid-Based SMEDDS Formulation of DIM, BR-9001,$973,931
N01 · FY2018 · CA
STUDIES TO EVALUATE THE TOXIC AND CARCINOGENIC POTENTIAL OF CELL PHONE RADIATION$888,267
N01 · FY2009 · ES